Family Planning Research Institute


       Family Planning Research Institute (FPRI) of TMC was established in 1979 by the Ministry of Health of China. It is the first institute that combines teaching, research and clinical work together. By now, it is the unique institute affiliated to the university, and is the top 3 in the discipline of family planning medicine in China.

It has 3 departments and one affiliated hospital with all the qualification for human assisted reproductive technology. At present, there are 22 faculties, including 1 academician of the Chinese Academy of Sciences, 8 professors, 6 associated professors and 3 lecturers. Over 89% of them have the experience of studying abroad.

The Department of Reproductive Biology & Genetics is composed of developmental biology research group, molecular andrology research group, reproductive genetics research group and gene editing research group. It mainly engaged in germ cells (sperm and oocytes) related research including maturation, aging and apoptosis, as well as studies of epigenetic regulation of reproductive system diseases caused by environmental, dietary and other factors. It is also committed to continue to the clinical studies of family planning / reproductive health technologies and products. 

The Department of Reproductive Immunology & Epidemiology are divided into two fields: basic research and applied basic research. For basic research, the research office is dedicated to: (1) to investigate the effect and mechanism of immune factors in normal pregnancy and pathological pregnancy disease (pre eclampsia and recurrent abortion); (2) to investigate the effect and mechanism of immune factors in male and female infertility; (3) to investigate the effect and mechanism of immune factors in the repeated failure in the implementation of human assisted reproductive technology; (4) to develop biosensor based on nucleic acid,protein, nano materials and its application in molecular diagnosis of disease; (5) to carry out infertility, birth defects, reproductive tract infection epidemiology; investigate the treatment and prevention of sexually transmitted diseases in new ways. For applied basic research, the research office is dedicated to: (1) to explore a new noninvasive biomarker for the warning of pathological pregnancy, monitoring, prenatal diagnosis and diagnosis of male infertility and the diagnosis of tumors of the reproductive system and real-time monitoring; (2) to explore the new method of contraception immunization.

The Department of Reproductive Pharmacology & Reproductive Endocrinology focuses on the hotspots and difficulties in the field of reproductive health, and studies in reproductive pharmacology, reproductive endocrine related diseases, assisted reproductive technology and stem cell technology.

FPRI is the member of both the National Key Disciplines of ObstetricsGynecology and the National Clinical Research Center for the Diseases of ObstetricsGynecology. It owns the following platforms for teaching and scientific research:

         1.  The National & Local Joint Engineering Lab for the New Contraception and Steril Technologies;

         2.  The clinical drug trial institution for reproductive health and infertility approved by CFDA;

         3.  The teaching platform for reproductive health approved by the Ministry of Education of China;

         4.  Human sperm bank of Hubei province approved by Ministry of Health of China;

         5.  Population and Family Planning Research Institute co-established by Hubei province and Huazhong University of Science and Technology;

        6.  The member of the key discipline of pharmacology in Hubei province;

        7.  Clinical research center for male infertility approved by Hubei province;

        8.  Hubei engineering lab for contraception and sterility.